Antibody Drugs: Technologies and Global Markets
Report Scope:
This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.
BCC Research analyzes and makes projections of each market and its applications, along with an analysis of the regulatory environment, new products, and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd., and Merck & Co.
The report covers the major markets of the U.S., Europe, and the emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and others.
Monoclonal antibodies are protein-based therapies/drugs that are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis, and cardiovascular diseases.
The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human, and humanized antibodies.
This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use.
Report Includes:
This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.
BCC Research analyzes and makes projections of each market and its applications, along with an analysis of the regulatory environment, new products, and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd., and Merck & Co.
The report covers the major markets of the U.S., Europe, and the emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and others.
Monoclonal antibodies are protein-based therapies/drugs that are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis, and cardiovascular diseases.
The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human, and humanized antibodies.
This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use.
Report Includes:
- 30 data tables and 29 additional tables
- An overview of the global market for antibody drugs and related applications and technologies
- Analyses of global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Identification of new opportunities, challenges, and technological changes within the industry and highlights of the market potential for antibody drugs by type, application, and region
- Detailed analysis of the current market trends, market forecast, and discussion of technological, and regulatory elements that are affecting the future marketplace
- Details of antibody functions, its comparison with antigen, and description of monoclonal antibodies, their history, advantages and disadvantages, types, manufacturing technologies and applications
- Coverage of new approvals, recalls, safety alerts and clinical trials of monoclonal antibodies and information on technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
- Information about major technologies for the formulation of antibody drugs and assessment of their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Comprehensive company profiles of the leading players including F. Hoffmann-La Roche Ltd., Johnson & Johnson Inc., Novartis AG, Biogen Inc., Amgen Inc., and Merck & Co.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
What's New in This Update?
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Antibodies and Antigens
Antibody Functions
Monoclonal Antibodies
History of Monoclonal Antibodies
Monoclonal Antibodies: Advantages and Disadvantages
Types of Monoclonal Antibodies
Manufacturing Technologies of Monoclonal Antibodies
Applications of Monoclonal Antibodies
CHAPTER 4 MARKET DYNAMICS
Technical Issues and HAMA Problem
Human Anti-mouse Antibody (HAMA)
Factors Affecting mAb Drugs
Market Drivers
Increasing Prevalence of Chronic Diseases
Aging Population
Advancements in Manufacturing Technologies
New Product Launches
Licensing and Collaboration Agreements
Market Challenges
Price Controls
Regulatory Approval Pressures
Entry of Biosimilars
Impact of COVID-19 on Antibody Drugs Market
CHAPTER 5 MARKET BREAKDOWN BY TECHNOLOGY TYPE
Market by Type
Market Overview
Market Revenue
Market Share
Market by Region
Market Overview
Market Revenue
Market Share
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Human Monoclonal Antibodies
Murine Monoclonal Antibodies
Market by Manufacturing Process
Market Overview
Market Revenue
Market Share
Market Analysis of Humanized Monoclonal Antibodies by Manufacturing Process
Market Analysis of Chimeric Monoclonal Antibodies by Manufacturing Process
Market Analysis of Human Monoclonal Antibodies by Manufacturing Process
Market of Murine Monoclonal Antibodies by Manufacturing Process
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Market by Diseases
Market Overview
Market Revenue
Market Share
Autoimmune Disease
Solid Tumors
Lymphoma, Leukemia and Multiple Myeloma
Others
CHAPTER 7 REGULATORY ASPECTS
New Approvals of Monoclonal Antibodies
Recalls and Safety Alerts
CHAPTER 8 PATENT REVIEW/ NEW DEVELOPMENTS
New Developments
Clinical Trial Phases
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV Clinical Trials
CHAPTER 9 COMPETITIVE LANDSCAPE
Mergers and Acquisitions
Antibody Drugs
Market Shares of Humanized Monoclonal Antibodies
Market Shares of Human Monoclonal Antibodies
Market Shares of Chimeric Monoclonal Antibodies
Market Shares of Murine Monoclonal Antibodies
CHAPTER 10 COMPANY PROFILES
ABBVIE INC.
AMGEN INC.
ALEXION PHARMACEUTICALS
ASTRAZENECA PHARMACEUTICALS
BIOGEN
BRISTOL-MYERS SQUIBB CO
ELI LILLY
F. HOFFMANN-LA ROCHE AG
FRESENIUS KABI
GLAXOSMITHKLINE
GENMAB A/S
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO. INC.
MERCK KGAA
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS
SANOFI S.A.
SEAGEN
TAKEDA PHARMACEUTICAL CO., LTD.
UCB CO.
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
What's New in This Update?
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Antibodies and Antigens
Antibody Functions
Monoclonal Antibodies
History of Monoclonal Antibodies
Monoclonal Antibodies: Advantages and Disadvantages
Types of Monoclonal Antibodies
Manufacturing Technologies of Monoclonal Antibodies
Applications of Monoclonal Antibodies
CHAPTER 4 MARKET DYNAMICS
Technical Issues and HAMA Problem
Human Anti-mouse Antibody (HAMA)
Factors Affecting mAb Drugs
Market Drivers
Increasing Prevalence of Chronic Diseases
Aging Population
Advancements in Manufacturing Technologies
New Product Launches
Licensing and Collaboration Agreements
Market Challenges
Price Controls
Regulatory Approval Pressures
Entry of Biosimilars
Impact of COVID-19 on Antibody Drugs Market
CHAPTER 5 MARKET BREAKDOWN BY TECHNOLOGY TYPE
Market by Type
Market Overview
Market Revenue
Market Share
Market by Region
Market Overview
Market Revenue
Market Share
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Human Monoclonal Antibodies
Murine Monoclonal Antibodies
Market by Manufacturing Process
Market Overview
Market Revenue
Market Share
Market Analysis of Humanized Monoclonal Antibodies by Manufacturing Process
Market Analysis of Chimeric Monoclonal Antibodies by Manufacturing Process
Market Analysis of Human Monoclonal Antibodies by Manufacturing Process
Market of Murine Monoclonal Antibodies by Manufacturing Process
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Market by Diseases
Market Overview
Market Revenue
Market Share
Autoimmune Disease
Solid Tumors
Lymphoma, Leukemia and Multiple Myeloma
Others
CHAPTER 7 REGULATORY ASPECTS
New Approvals of Monoclonal Antibodies
Recalls and Safety Alerts
CHAPTER 8 PATENT REVIEW/ NEW DEVELOPMENTS
New Developments
Clinical Trial Phases
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV Clinical Trials
CHAPTER 9 COMPETITIVE LANDSCAPE
Mergers and Acquisitions
Antibody Drugs
Market Shares of Humanized Monoclonal Antibodies
Market Shares of Human Monoclonal Antibodies
Market Shares of Chimeric Monoclonal Antibodies
Market Shares of Murine Monoclonal Antibodies
CHAPTER 10 COMPANY PROFILES
ABBVIE INC.
AMGEN INC.
ALEXION PHARMACEUTICALS
ASTRAZENECA PHARMACEUTICALS
BIOGEN
BRISTOL-MYERS SQUIBB CO
ELI LILLY
F. HOFFMANN-LA ROCHE AG
FRESENIUS KABI
GLAXOSMITHKLINE
GENMAB A/S
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO. INC.
MERCK KGAA
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS
SANOFI S.A.
SEAGEN
TAKEDA PHARMACEUTICAL CO., LTD.
UCB CO.
LIST OF TABLES
Summary Table: Global Market for Antibody Drugs, by Antibody Type, Through 2026
Table 1: Evolution of Monoclonal Antibodies
Table 2: Advantages and Disadvantages of Monoclonal Antibodies
Table 3: Murine Monoclonal Antibodies
Table 4: Chimeric Monoclonal Antibodies
Table 5: Humanized Monoclonal Antibodies
Table 6: Human Monoclonal Antibodies
Table 7: Differences between Hybridoma and Recombinant Technologies
Table 8: Murine Monoclonal Antibodies and Their Applications
Table 9: Chimeric Monoclonal Antibodies and Their Applications
Table 10: Human Monoclonal Antibodies and Their Applications
Table 11: Humanized Monoclonal Antibodies and Their Applications
Table 12: Global Market for Antibody Drugs, by Antibody Type, Through 2026
Table 13: Global Market for Antibody Drugs, by Region, Through 2026
Table 14: Global Market for Humanized Monoclonal Antibodies, by Region, Through 2026
Table 15: Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2026
Table 16: Global Market for Human Monoclonal Antibodies, by Region, Through 2026
Table 17: Global Market for Murine Monoclonal Antibodies, by Region, Through 2026
Table 18: Global Market for Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 19: Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 20: Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 21: Global Market for Human Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 22: Global Market for Murine Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 23: Global Market for Antibody Drugs, by Disease, Through 2026
Table 24: Types of Autoimmune Diseases
Table 25: Global Market for Antibody Drugs in Autoimmune Disease, by Antibody Type, Through 2026
Table 26: Global Market for Antibody Drugs in Autoimmune Disease, by Region, Through 2026
Table 27: Types of Cancer by the Tissue of Origin
Table 28: Global Market for Antibody Drugs in Solid Tumor, by Antibody Type, Through 2026
Table 29: Global Market for Antibody Drugs in Solid Tumor, by Region, Through 2026
Table 30: Types of Leukemia
Table 31: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Antibody Type, Through 2026
Table 32: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Region, Through 2026
Table 33: Global Market for Antibody Drugs in Other Diseases, by Antibody Type, Through 2026
Table 34: Global Market for Antibody Drugs in Other Diseases, by Region, Through 2026
Table 35: Newly Approved Monoclonal Antibodies, 2019-August 2021
Table 36: Recalls and Safety Alerts, 2019-August 2021
Table 37: Monoclonal Antibodies in Phase I Clinical Trials
Table 38: Monoclonal Antibodies in Phase II Clinical Trials
Table 39: Monoclonal Antibodies in Phase III Clinical Trials
Table 40: Monoclonal Antibodies in Phase IV Clinical Trials
Table 41: M&A: Pharmaceutical Companies
Table 42: AbbVie Inc.: Business Segment
Table 43: AbbVie Inc.: Financial Performance, Through 2020
Table 44: Amgen: Financial Performance, Through 2020
Table 45: AstraZeneca: Financial Performance, 2018-2020
Table 46: Bristol-Myers Squibb: Financial Performance, 2018-2020
Table 47: Eli Lilly: Business Segment
Table 48: Eli Lilly: Financial Performance, 2018-2020
Table 49: F. Hoffmann-La Roche: Business Segment
Table 50: F. Hoffmann-La Roche: Financial Performance, 2018-2020
Table 51: GlaxoSmithKline: Product Segment
Table 52: Johnson & Johnson: Business Segment
Table 53: Johnson & Johnson: Financial Performance, 2018-2020
Table 54: Merck & Co. Inc.: Business Segment
Table 55: Merck & Co. Inc.: Financial Performance, 2018-2020
Table 56: Pfizer: Business Segment
Table 57: Sanofi: Business Segment
Table 58: Sanofi: Financial Performance, 2018-2020
Summary Table: Global Market for Antibody Drugs, by Antibody Type, Through 2026
Table 1: Evolution of Monoclonal Antibodies
Table 2: Advantages and Disadvantages of Monoclonal Antibodies
Table 3: Murine Monoclonal Antibodies
Table 4: Chimeric Monoclonal Antibodies
Table 5: Humanized Monoclonal Antibodies
Table 6: Human Monoclonal Antibodies
Table 7: Differences between Hybridoma and Recombinant Technologies
Table 8: Murine Monoclonal Antibodies and Their Applications
Table 9: Chimeric Monoclonal Antibodies and Their Applications
Table 10: Human Monoclonal Antibodies and Their Applications
Table 11: Humanized Monoclonal Antibodies and Their Applications
Table 12: Global Market for Antibody Drugs, by Antibody Type, Through 2026
Table 13: Global Market for Antibody Drugs, by Region, Through 2026
Table 14: Global Market for Humanized Monoclonal Antibodies, by Region, Through 2026
Table 15: Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2026
Table 16: Global Market for Human Monoclonal Antibodies, by Region, Through 2026
Table 17: Global Market for Murine Monoclonal Antibodies, by Region, Through 2026
Table 18: Global Market for Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 19: Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 20: Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 21: Global Market for Human Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 22: Global Market for Murine Monoclonal Antibodies, by Manufacturing Process, Through 2026
Table 23: Global Market for Antibody Drugs, by Disease, Through 2026
Table 24: Types of Autoimmune Diseases
Table 25: Global Market for Antibody Drugs in Autoimmune Disease, by Antibody Type, Through 2026
Table 26: Global Market for Antibody Drugs in Autoimmune Disease, by Region, Through 2026
Table 27: Types of Cancer by the Tissue of Origin
Table 28: Global Market for Antibody Drugs in Solid Tumor, by Antibody Type, Through 2026
Table 29: Global Market for Antibody Drugs in Solid Tumor, by Region, Through 2026
Table 30: Types of Leukemia
Table 31: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Antibody Type, Through 2026
Table 32: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Region, Through 2026
Table 33: Global Market for Antibody Drugs in Other Diseases, by Antibody Type, Through 2026
Table 34: Global Market for Antibody Drugs in Other Diseases, by Region, Through 2026
Table 35: Newly Approved Monoclonal Antibodies, 2019-August 2021
Table 36: Recalls and Safety Alerts, 2019-August 2021
Table 37: Monoclonal Antibodies in Phase I Clinical Trials
Table 38: Monoclonal Antibodies in Phase II Clinical Trials
Table 39: Monoclonal Antibodies in Phase III Clinical Trials
Table 40: Monoclonal Antibodies in Phase IV Clinical Trials
Table 41: M&A: Pharmaceutical Companies
Table 42: AbbVie Inc.: Business Segment
Table 43: AbbVie Inc.: Financial Performance, Through 2020
Table 44: Amgen: Financial Performance, Through 2020
Table 45: AstraZeneca: Financial Performance, 2018-2020
Table 46: Bristol-Myers Squibb: Financial Performance, 2018-2020
Table 47: Eli Lilly: Business Segment
Table 48: Eli Lilly: Financial Performance, 2018-2020
Table 49: F. Hoffmann-La Roche: Business Segment
Table 50: F. Hoffmann-La Roche: Financial Performance, 2018-2020
Table 51: GlaxoSmithKline: Product Segment
Table 52: Johnson & Johnson: Business Segment
Table 53: Johnson & Johnson: Financial Performance, 2018-2020
Table 54: Merck & Co. Inc.: Business Segment
Table 55: Merck & Co. Inc.: Financial Performance, 2018-2020
Table 56: Pfizer: Business Segment
Table 57: Sanofi: Business Segment
Table 58: Sanofi: Financial Performance, 2018-2020
LIST OF FIGURES
Summary Figure: Global Market for Antibody Drugs, by Antibody Type, 2019-2026
Figure 1: Global Market for Antibody Drugs, by Antibody Type, 2019-2026
Figure 2: Global Market Shares of Antibody Drugs, by Antibody Type, 2020
Figure 3: Global Market for Antibody Drugs, by Region, 2019-2026
Figure 4: Global Market Shares of Antibody Drugs, by Region, 2020
Figure 5: Global Market for Humanized Monoclonal Antibodies, by Region, 2019-2026
Figure 6: Global Market for Chimeric Monoclonal Antibodies, by Region, 2019-2026
Figure 7: Global Market for Human Monoclonal Antibodies, by Region, 2019-2026
Figure 8: Global Market for Murine Monoclonal Antibodies, by Region, 2019-2026
Figure 9: Global Market for Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 10: Global Market Shares of Antibody Drugs, by Manufacturing Process, 2020
Figure 11: Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 12: Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 13: Global Market for Human Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 14: Global Market for Murine Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 15: Global Market for Antibody Drugs, by Disease, 2019-2026
Figure 16: Global Market Shares of Antibody Drugs, by Disease, 2020
Figure 17: Global Market for Antibody Drugs in Autoimmune Disease, by Antibody Type, 2019-2026
Figure 18: Global Market for Antibody Drugs in Autoimmune Disease, by Region, 2019-2026
Figure 19: Global Market for Antibody Drugs in Solid Tumor, by Antibody Type, 2019-2026
Figure 20: Global Market for Antibody Drugs in Solid Tumor, by Region, 2019-2026
Figure 21: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Antibody Type, 2020-2026
Figure 22: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Region, 2020-2026
Figure 23: Global Market for Antibody Drugs in Other Diseases, by Antibody Type, 2020-2026
Figure 24: Global Market for Antibody Drugs in Other Diseases, by Region, 2020-2026
Figure 25: Global Market Shares of Humanized Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 26: Global Market Shares of Human Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 27: Global Market Shares of Chimeric Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 28: Global Market Shares of Murine Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 29: AbbVie Inc.: Net Revenue Share, by Business Segment, 2020
Figure 30: AbbVie Inc.: Net Revenue Share, by Region, 2020
Figure 31: Amgen: Sales Share, by Product, 2020
Figure 32: Amgen: Revenue Share, by Region, 2020
Figure 33: AstraZeneca: Sales Share, by Segment, 2020
Figure 34: AstraZeneca: Revenue Share, by Region, 2020
Figure 35: Bristol Myers Squibb: Sales Share, by Product, 2020
Figure 36: Bristol-Myers Squibb: Total Revenue Share, by Region, 2020
Figure 37: Eli Lilly: Total Sales Share, by Product Segment, 2020
Figure 38: Eli Lilly: Total Revenue Share, by Region, 2020
Figure 39: F. Hoffmann-La Roche: Total Sales Share, by Product Segment, 2020
Figure 40: F. Hoffmann-La Roche: Total Revenue Share, by Region, 2020
Figure 41: Johnson & Johnson: Total Sales Share, by Business Segment, 2020
Figure 42: Johnson & Johnson: Total Revenue Share, by Region, 2020
Figure 43: Merck & Co. Inc.: Revenue Share, by Business Segment, 2020
Figure 44: Merck & Co. Inc.: Revenue Share, by Region, 2020
Figure 45: Sanofi: Net Sales Share, by Business Segment, 2020
Figure 46: Sanofi: Net Sales Share, by Region, 2020
Summary Figure: Global Market for Antibody Drugs, by Antibody Type, 2019-2026
Figure 1: Global Market for Antibody Drugs, by Antibody Type, 2019-2026
Figure 2: Global Market Shares of Antibody Drugs, by Antibody Type, 2020
Figure 3: Global Market for Antibody Drugs, by Region, 2019-2026
Figure 4: Global Market Shares of Antibody Drugs, by Region, 2020
Figure 5: Global Market for Humanized Monoclonal Antibodies, by Region, 2019-2026
Figure 6: Global Market for Chimeric Monoclonal Antibodies, by Region, 2019-2026
Figure 7: Global Market for Human Monoclonal Antibodies, by Region, 2019-2026
Figure 8: Global Market for Murine Monoclonal Antibodies, by Region, 2019-2026
Figure 9: Global Market for Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 10: Global Market Shares of Antibody Drugs, by Manufacturing Process, 2020
Figure 11: Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 12: Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 13: Global Market for Human Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 14: Global Market for Murine Monoclonal Antibodies, by Manufacturing Process, 2019-2026
Figure 15: Global Market for Antibody Drugs, by Disease, 2019-2026
Figure 16: Global Market Shares of Antibody Drugs, by Disease, 2020
Figure 17: Global Market for Antibody Drugs in Autoimmune Disease, by Antibody Type, 2019-2026
Figure 18: Global Market for Antibody Drugs in Autoimmune Disease, by Region, 2019-2026
Figure 19: Global Market for Antibody Drugs in Solid Tumor, by Antibody Type, 2019-2026
Figure 20: Global Market for Antibody Drugs in Solid Tumor, by Region, 2019-2026
Figure 21: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Antibody Type, 2020-2026
Figure 22: Global Market for Antibody Drugs in Lymphoma, Leukemia and Multiple Myeloma, by Region, 2020-2026
Figure 23: Global Market for Antibody Drugs in Other Diseases, by Antibody Type, 2020-2026
Figure 24: Global Market for Antibody Drugs in Other Diseases, by Region, 2020-2026
Figure 25: Global Market Shares of Humanized Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 26: Global Market Shares of Human Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 27: Global Market Shares of Chimeric Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 28: Global Market Shares of Murine Monoclonal Antibodies, by Key Manufacturer/Supplier, 2020
Figure 29: AbbVie Inc.: Net Revenue Share, by Business Segment, 2020
Figure 30: AbbVie Inc.: Net Revenue Share, by Region, 2020
Figure 31: Amgen: Sales Share, by Product, 2020
Figure 32: Amgen: Revenue Share, by Region, 2020
Figure 33: AstraZeneca: Sales Share, by Segment, 2020
Figure 34: AstraZeneca: Revenue Share, by Region, 2020
Figure 35: Bristol Myers Squibb: Sales Share, by Product, 2020
Figure 36: Bristol-Myers Squibb: Total Revenue Share, by Region, 2020
Figure 37: Eli Lilly: Total Sales Share, by Product Segment, 2020
Figure 38: Eli Lilly: Total Revenue Share, by Region, 2020
Figure 39: F. Hoffmann-La Roche: Total Sales Share, by Product Segment, 2020
Figure 40: F. Hoffmann-La Roche: Total Revenue Share, by Region, 2020
Figure 41: Johnson & Johnson: Total Sales Share, by Business Segment, 2020
Figure 42: Johnson & Johnson: Total Revenue Share, by Region, 2020
Figure 43: Merck & Co. Inc.: Revenue Share, by Business Segment, 2020
Figure 44: Merck & Co. Inc.: Revenue Share, by Region, 2020
Figure 45: Sanofi: Net Sales Share, by Business Segment, 2020
Figure 46: Sanofi: Net Sales Share, by Region, 2020
